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Abstract 
Background: A folate‑receptor‑targeted poly (lactide‑co‑Glycolide) (PLGA)‑Polyethylene glycol (PEG) nanoparticle is 
developed for encapsulation and delivery of disulfiram into breast cancer cells. After a comprehensive characteriza‑
tion of nanoparticles, cell cytotoxicity, apoptosis induction, cellular uptake and intracellular level of reactive oxygen 
species are analyzed. In vivo acute and chronic toxicity of nanoparticles and their efficacy on inhibition of breast 
cancer tumor growth is studied.
Results: The folate‑receptor‑targeted nanoparticles are internalized into the cells, induce reactive oxygen species for‑
mation, induce apoptosis and inhibit cell proliferation more efficiently compared to the untargeted nanoparticles. The 
acute and toxicity test show the maximum dose of disulfiram equivalent of nanoparticles for intra‑venous injection is 
6 mg/kg while show significant decrease in the breast cancer tumor growth rate.
Conclusion: It is believed that the developed formulation could be used as a potential vehicle for successful delivery 
of disulfiram, an old and inexpensive drug, into breast cancer cells and other solid tumors.
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Background
Disulfiram (DS), a member of dithiocarbamate family 
with 297 Da molecular weight, is oral aldehyde dehydro-
genase (ALDH) inhibitor that has been used in the treat-
ment of alcoholism since 1940s [1–3]. During the last 
few years, a growing body of evidence from both in vivo 
and in vitro studies indicated that disulfiram has antican-
cer properties [2]. Anticancer properties of disulfiram 
have been demonstrated in pre-clinical models of hema-
tological malignancies and solid tumors [4, 5]. Several 
mechanisms have been proposed for disulfiram induced 
cytotoxic effects. It has been shown that DS directly 
interacts with matrix metalloproteinase MMP-2 and 
MMP-9 and inhibits their proteolytic activity through 
a zinc chelating mechanism [2]. In  vitro, DS has shown 
the ability to induce cytotoxic effects in cancer cells and 
inhibits the proteasome and NF- κB activities; as well as 
TNF-α-induced nuclear factor-KB (NF-κB) translocation 
[2]. DS has shown to be able to reduce P-glycoprotein 
(P-gp)-mediated drug resistance to vinblastine and col-
chicine by targeting P-gp itself [2]. DS is a highly reac-
tive compound and its first metabolite, DDTC, react with 
many molecules and proteins in the cells. The cytotoxic 
effect of DS on the cancer cells has been also attributed 
to many other parameters including inhibition of DNA 
methyltransferase [6], reduction DNA replication [7], 
induction of oxidative stress [8], induction of mitochon-
drial membrane permeabilization, cell cycle arrest [8], 
inhibition of proteasome activity [1, 3, 7, 9, 10], inhibition 
of superoxide dismutase and increase intracellular reac-
tive oxygen species (ROS) [1, 4]. The anticancer activity 
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of DS is copper (Cu) dependent [11]. It means that the 
redox conversion of disulfiram is specific to Cu (II) and 
no other biological metal ions such as Fe (II or III) and 
Mn(III) [19]. Based on the chemical structure of DS it is 
speculated that the interaction between the drug and Cu 
(II) would be through its thiol groups [4]. In the gastro-
intestinal system DS is rapidly converted to bis (diethyl-
dithiocarbamate) Cu complex. It could also be degraded 
into diethyldithiocarbamate (DDTC) during the absorp-
tion into the blood stream [4, 12].
Although the metabolisms and clinical pharmacology 
of DS are fairly understood; its potential application in 
cancer treatment is still hampered by its currently avail-
able oral formulation [12]. DS is extremely unstable in 
acidic gastric environment and is also rapidly degraded in 
blood stream [4, 12]. For example after an oral adminis-
tration of a 500 mg of DS, its blood concentration would 
be still below the limit of detection [12]. Therefore, an 
efficient drug delivery system is essential for clinical 
application of DS in cancer treatment [12]. One strategy 
would be the encapsulation of DS into nanoparticles to 
protect it from degradation in blood system [12]. The 
targeted delivery of DS encapsulated nanoparticles into 
tumor cells could increase the drug accumulation at the 
tumor site [13–16]; and would enhance the endurance of 
the drug in blood circulation [13–16].
Poly (lactic-co-glycolic acid) (PLGA) has received con-
siderable attention due to its attractive properties includ-
ing biodegradability, biocompatibility, FDA approval for 
delivery systems, protection of drug from degradation, 
and possibility of sustained release [17]. PLGA-based 
nanoparticles have gained great interest in diagnostics 
and applications such as sustained drug release systems 
[18]. PLGA NPs have been used to develop proteins, pep-
tides and nucleic acid based pharmaceutics. These NPs 
extravasate through the tumour vasculature and deliver 
the therapeutic agent into the cells by enhancing permea-
bility and retention (EPR) effect [19]. In this study, a novel 
system for delivery of DS is developed using PLGA nano-
particles (NPs). Nanoprecipitation method is used for 
preparation of nanoparticles [18, 20]. In order to prevent 
the elimination of DS by liver and spleen from the blood 
stream, the surface of NPs is modified by hydrophilic 
polyethylene glycol (PEG) [4]. As we intend to deliver the 
nanoparticles into breast cancer cells mainly via receptor 
mediated endocytosis, the surface of NPs is also modi-
fied with folate. The folate receptor is overexpressed on 
the vast majority of cancer tissues, while its expression 
is limited in healthy tissues and organs. Folate recep-
tors are highly expressed in epithelial, ovarian, cervical, 
breast, lung, kidney, colorectal and brain tumors [18]. 
Folate mediated cancer cell targeting is one of the most 
important methods for active targeting of therapeutic 
agents into cancer cells [21]. This is the first attempt for 
DS encapsulation into PEG-PLGA-folate NPs and its 
potential application in cancer treatment. It is presumed 
that the injection of NPs into the blood stream, protects 
the drug from rapid degradation, assists its delivery into 
specific tumor site and releases it in a sustained manner.
Methods
Materials
Poly (lactide-co-glycolide) (PLGA) (RG 504 H, acid termi-
nated, lactide:glycolide 50:50, Mw: 38,000), Poly(ethylene 
glycol) (PEG)-bis-amine (Mn: 10,000), Poly(vinyl alco-
hol) (Mw: 31,000–50,000), folate, fluorescein-5-iso-
thiocyanate (FITC), N,N′-Dicyclohexylcarbodiimide 
(DCC), Dichloromethane (DCM) and sulfo-N-hydrox-
ysuccinimide (NHS) were obtained from Sigma-Aldrich 
(St. Louise, MO, USA); disulfiram, methylene chloride, 
diethyl ether, methanol and dimethyl sulfoxide (DMSO) 
was obtained from Merck (Darmstadt, Germany); Fetal 
bovine serum (FBS), DMEM media, PBS buffer, Trypsin/
EDTA and penicillin–streptomycin were purchased from 
GIBCO (Maryland, USA); MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5- diphenyltetrazolium bromide) assay kit was 
obtained from Roche (Mannhein, Germany).
Preparation and characterization of PLGA‑PEG‑folate 
conjugate
The synthesis of PLGA-PEG-Folate conjugate was previ-
ously described [18, 20]. Briefly, 2 g PLGA was dissolved 
in 15 mL of methylene chloride and the terminal carboxyl 
group of polymer was activated by addition of 207  mg 
DCC and 115 mg NHS to the solution at room tempera-
ture under nitrogen atmosphere for 24  h. The resultant 
solution was filtered to remove by-products from acti-
vated PLGA that precipitated by dropping into ice-cold 
diethyl ether. The activated PLGA was dried under vac-
uum and dissolved in 16  mL methylene chloride. The 
resultant solution was slowly added into PEG-bis-amine 
solution (200  mg/4  mL methylene chloride) in a molar 
ratio of 1:10 for activated PLGA/PEG-bis-amine. The 
reaction was carried out for 24 h under nitrogen atmos-
phere and the resultant solution was precipitated by the 
addition of ice-cold diethyl ether. The amine-terminated 
di-block copolymer PLGA-PEG-NH2, was obtained, fil-
tered and vacuum dried.
For conjugation of folic acid to PLGA-PEG-NH2 di-
block copolymer, 500 mg of PLGA-PEG-NH2 (dissolved 
in 5  mL DMSO) was mixed with 13  mg folic acid and 
13 mg DCC. The reaction was performed at room tem-
perature for 7  h. The resultant solution was added to 
100 mL cold methanol and filtered by a paper filter. The 
precipitated product was dried under vacuum and dis-
solved in 50 mL DCM for separation of free folate from 
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conjugated folate. The solution centrifuged at 21,000g to 
isolate the free folate precipitation in DCM. The super-
natant was dried under the vacuum (Fig. 1). The synthetic 
PLGA-PEG-folate was characterized using 1H NMR, 
FTIR and LC–MS analyses methods.
Nanoparticle preparation
For preparation of nanoparticles, nanoprecipitation 
method was used [18]. Briefly, the appropriate amount 
of polymer (PLGA or PLGA-PEG-Folate) and disulfiram 
was dissolved in a DMSO to form a diffusing phase. In 
synthesis of disulfiram encapsulated PLGA-PEG-folate 
nanoparticle, a combination of PLGA-PEG-folate and 
PLGA ranging from (1:1) to (1:10) was chosen. The ratio 
of drug (disulfiram) to polymer (PLGA or PLGE-PEG-
Folate) was 1:10 (w/w). The mixture was then added into 
the dispersing phase (PVA 0.5 % in water) using a syringe 
that positioned directly in the medium under moderate 
magnetic stirring (300 rpm, 10 min). The ratio of diffus-
ing phase to dispersing phase was 1:20 (v/v). The freshly 
formed nanoparticles were obtained by dialyzing against 
water for 24  h. The nanoparticles were centrifuged at 
20,000g for 15 min to remove DMSO and free disulfiram 
followed by several washing steps with distilled water. 
The purity of NPs was analyzed using spectrophotom-
etry. The absence of DMSO in nanoparticle solution (in 
PBS) was confirmed at 265 nm, the absence of un-capsu-
lated disulfiram was confirmed at 433 nm. The nanopar-
ticles were then freeze-dried and kept at 4 °C.
Characterization of nanoparticles
The mean particle size of the PLGA NPs was determined 
by dynamic light scattering using photon correlation 
spectroscopy. The measurements were performed using 
a Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, 
UK) equipped with a helium–neon laser at 25  °C and a 
scattering angle of 173°. The morphological examination 
of NPs was performed using a field emission scanning 
electron microscope at an accelerating voltage of 5  kV. 
A drop of diluted nanoparticle solution was placed onto 
Fig. 1 A representation of PLGA‑PEG‑folate synthesis and NPs preparation procedure
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a copper sheet and dried. For scanning electron micros-
copy (SEM) analysis, the surfaces of NPs were sputtered 
with gold in a vacuum before examination under the 
microscope.
Drug loading and release behavior of NPs
To determine the drug loading and encapsulation effi-
ciency of disulfiram in NPs, 150  mg of dried NPs was 
dispersed in 15 mL phosphate-buffered saline (PBS) solu-
tion (pH 7.4) to obtain a final concentration of 10  mg/
mL. 10  μL of NPs suspension was added to 90  μL of 
DMSO to dissolve the PLGA and release the encapsu-
lated disulfiram. The sample was vortexed for 30  s and 
900  μL methanol was added to precipitate the PLGA 
polymer. The solution was mixed again, centrifuged and 
the supernatant was removed and analyzed by UV–Vis-
ible spectroscopy (433  nm) to estimate the amount of 
encapsulated disulfiram in NPs. A standard curve was 
prepared by making serial dilutions of disulfiram: cupper 
(1:1 molar ratio) in DMSO with specific concentrations 
[22]. The encapsulation efficacy (EE) was measured as 
the mass ratio of disulfiram encapsulated in NPs to that 
of used in the NPs preparation. The drug loading was 
determined as the weight ratio of disulfiram in NPs to the 
weight of NPs.
For the release behavior, NPs were dispersed in 
PBS (0.1  M pH: 7.4) at 37  °C and sealed in dialysis bag 
(MWCO: 12  kDa) and immersed in PBS with continu-
ous shaking at 100 rpm. After 0, 24, 48, 72, 96 and 120 h, 
all release media were taken out and replenished with an 
equal volume of fresh PBS. The amount of released disul-
firam was measured using HPLC method [14].
MTT assay
The cytotoxicity of disulfiram encapsulated PLGA-
PEG-folate NPs (DS-PPF-NPs), disulfiram encapsulated 
PLGA NPs (DS-P-NPs) and blank PLGA-PEG-folate NPs 
(PPF-NPs) on breast cancer cells (MCF7 and 4T1) was 
determined via the reduction of 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide (MTT, Sigma) 
to Formazan. Briefly, MCF7 and 4T1 (mice breast cancer 
cell line) cells were seeded at 5000/well in flat-bottom 
96-well culture plate and incubated with different con-
centrations (0, 100, 200, 300, 400, 500, 750, 1000, 1250, 
1500 and 2000  nM disulfiram equivalent) of DS-PPF-
NPs, DS-P-NPs, PPF-NPs and free disulfiram for 24  h. 
After removing the media, cells were further incubated 
with MTT solution (5  mg/ml in PBS) at 37  °C and the 
untreated cells were used as control. After 3  h of incu-
bation, the supernatant was removed and the cells were 
further treated with 100 µL of DMSO to dissolve the dark 
blue crystals of formazan and the absorbance was meas-
ured with an ELISA reader at 570 nm.
Uptake of NPs by breast cancer cells
To quantitatively assess DS-PPF-NPs uptake by MCF7 
cells, the fluorescein isothiocyanate (FITC) was added to 
the diffusing phase in NPs preparation process to obtain 
FITC labeled DS-PPF-NPs and FITC labeled DS-P-NPs. 
The FITC labeled NPs were incubated with MCF7 cells in 
6-well plates (in 2  ml serum free basic medium/well) for 
4 h. After removing the media, the cells were washed with 
PBS, trypsinized, centrifuged, and suspended in PBS for 
flowcytometry analysis (excitation/emission 350/461 nm). 
The instrument threshold for the negative control sam-
ple (untreated MCF7) was setup at  ~1  % level. The per-
centage of cells exhibiting FITC-fluorescence beyond 
this threshold value was calculated as a function of NPs 
uptake [23]. The uptake of DS-P-NPs and DS-PPF-NPs 
was further performed in the presence and absence of 
folate. Briefly, MCF-7 cells were pretreated with or with-
out folate (500 nM) overnight and seeded onto a 24-well 
plate (10,000 cells per well) with DMEM. The FITC labeled 
NPs were incubated with MCF-7 cells for 4 h. After several 
washing steps, the uptake of NPs was analyzed using flow-
cytometry. Moreover, the presence of NPs in breast can-
cer cells (MCF7) was examined by fluorescent microscopy. 
The nucleus of cells was stained using DAPI. Briefly, the 
cells were trypsinized, washed with PBS and fixed using 
3.7 % formaldehyde for 10 min. The cells were washed and 
treated with 0.2  % Triton X-100 for 5  min and the cells 
treated with an appropriate amount of DAPI labeling solu-
tion (1:5000 DAPI in PBS) for 5 min. After washing with 
PBS cells were analyzed with fluorescent microscopy.
Quantification of apoptosis using PI/Hoechst 3342 staining
To explore the effect of NPs on breast cancer cells apop-
tosis and to determine the efficiency of targeting agent 
(Folate) for induction of apoptosis, Chromatin Conden-
sation/Dead Cell Apoptosis assay was performed [24]. 
Briefly, MCF7 cells were treated with DS-PPF-NPs, DS-
P-NPs, PLGA NPs (without disulfiram) and PPF-NPs 
(without disulfiram) for 24  h with drug concentration 
of 250 nM disulfiram equivalent. Apoptosis was quanti-
fied by Chromatin Condensation/Dead Cell Apoptosis 
Kit using Hoechst 33342 and Propidium iodide (PI) for 
flowcytometry. First, the treated cells were washed with 
cold phosphate-buffered saline (PBS) and the cell density 
was adjusted to 5 × 105 cells/mL. Then 1 μL of the Hoe-
chst 33342 stock solution (5.0 mg/ml solution in water) 
and 1  μL of the PI stock solution (1.0  mg/ml solution 
in water) were added to 1  mL of cell suspension. After 
20 min incubation on ice, the stained cells were evaluated 
by flowcytometry (PartecPasIII, Germany) using exci-
tation/emission 350/461 and 535/617  nm for Hoechst 
33342 and PI, respectively. The data was collected and 
analyzed with FlowMax software.
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Clonogenic assay
To determine the effect of disulfiram encapsulated 
NPs and free disulfiram on colony forming capability 
of breast cancer cells, clonogenic assay was performed 
[16]. Briefly, MCF7 cells (5 × 104/well) were cultured in 
6-well plates overnight and exposed to 500  nM of free 
disulfiram, DS-PPF-NPs and DS-P-NPs with drug con-
centration of 250 nM disulfiram equivalent for 12 h. The 
cells were collected and cultured in 6-well plates con-
taining drug-free medium at a density of 250/well. The 
clonogenic cells were considered as the ones with the 
ability to form a colony consist of at least 50 cells after 
10 days of culture.
Measurement of ROS activity
To determine the oxidative stress of the treated cells, 
dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay 
was performed. This test is a quantitative method for 
detection of intracellular production of ROS. DCFH-DA 
(uncharged) is taken up by cells and cleaved by nonspe-
cific esterases to create DCFH (charged) which is further 
oxidized by ROS to make DCF which is highly fluores-
cent. After incubation with desired concentration of 
disulfiram, DS-P-NPs and DS-PPF-NPs for 24  h, breast 
cancer cells (MCF7) were exposed to 10 μM DCFH-DA 
and incubated for 30 min at 37° C. The cells were washed 
twice with PBS and resuspended in PBS. Finally, fluo-
rescence intensity of the samples was detected by fluo-
rescence spectrophotometer (Cary Eclipse, USA) with 
excitation at 485 nm and emission at 530 nm [24].
Acute and chronic toxicity tests
Thirty-six 5-week-old male BALB/c mice weighing an 
average of 25 g (Institute of Pasture, Tehran, Iran) were 
selected to study the acute and chronic toxicity of DS-
PPF-NPs. In acute toxicity test, 100  mg/kg of DS-PPF-
NPs was given as starting dose. The animals were divided 
into 5 groups, each consisting of 4 mice as follows:
Group 1: control (200 μL of PBS).
Group 2: 2000  mg/kg DS-PPF-NPs (equivalent to 
100 mg/kg disulfiram).
Group 3: 225  mg/kg DS-PPF-NPs (equivalent to 
12.5 mg/kg disulfiram).
Group 4: 120 mg/kg DS-PPF-NPs (equivalent to 6 mg/
kg disulfiram).
Group 5: 60  mg/kg DS-PPF-NPs (equivalent to 3  mg/
kg disulfiram).
In animal study, the NPs administered intravenously 
into the tail vein of animals except the 2000 and 225 mg/
kg NPs which administered using intraperitoneal routeas 
these doseswere too high to be administer intravenously. 
After 24  h, animals were sacrificed and the abnormal 
hematological indices were screened.
According to the results of acute toxicity test, the 
chronic toxicity test was performed using the following 
groups:
Group 1: control (120  mg/kg PPF-NPs) (NPs without 
disulfiram).
Group 2: 120 mg/kg DS-PPF-NPs (equivalent to 6 mg/
kg disulfiram).
Group 3: 60  mg/kg DS-PPF-NPs (equivalent to 3  mg/
kg disulfiram).
Group 4: 30 mg/kg DS-PPF-NPs (equivalent to 1.5 mg/
kg disulfiram).
Group 5: 15  mg/kg DS-PPF-NPs (equivalent to 
0.75 mg/kg disulfiram).
For chronic toxicity test, the drug was administered for 
7 consecutive days. In all groups, the drug was dissolved 
in PBS (200 μL) and administered intravenously via 1 ml 
syringe. Animals were sacrificed 7 days after drug admin-
istration and the abnormal hematological indices were 
screened. The anesthesia of animals was performed using 
ketamine/xylazin (8/1 mg per 100 g body weight of ani-
mals) and the blood samples were directly taken from 
animals heart using 1–3  mL syringe. The animals were 
then sacrificed using diethyl ether anesthesia.
Blood samples were taken for clinical chemistry tests. 
Total leukocyte count (WBC), erythrocyte count (RBC), 
platelets (Plt), hemoglobin (Hgb), hematocrit (Hct), mean 
cell volume (MCV) and mean corpuscular hemoglobin 
concentration (MCHC), were measured using an animal 
blood counter (Celltac; Nihon Kohden, Tokyo, Japan). 
Plasma urea nitrogen (Urea), creatinine (Cr), and glucose 
(Glu) were determined using CCX System (CCX  WB; 
Nova Biomedical, USA). Plasma alkaline phosphatase 
(ALP), albumin (ALB), direct bilirubin (DBil) were also 
measured (Autoanalyser Model Biotecnica,  BT3500, 
Rome, Italy).
Inhibition of breast cancer growth in mouse model
The effect of disulfiram, DS-P-NPs and DS-PPF-NPs on 
suppression of breast cancer tumor growth in  vivo was 
performed. Five-week-old female BALB/c mice (Insti-
tute of Pasture, Tehran, Iran) were housed according to 
the relevant laws and guidelines for animal care set forth 
by institutional laboratory animal care. The 4T1 tumor 
model was generated by an orthotropic injection consists 
of 1 × 106 cells in 50 μL PBS into the mammary fat pad 
of the mice. After the tumor volume was reached to 200–
250  mm3, tumor bearing mice were randomly divided 
into four groups (n = 3).
Group 1: control (200 mg/kg of blank NPs in 200 μL of 
PBS).
Group 2: control (10 mg/kg of free disulfiram in PBS).
Group 3: 200  mg/kg DS-P-NPs in PBS (equivalent to 
10 mg/kg disulfiram).
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Group 4: 200 mg/kg DS-PPF-NPs in PBS (equivalent to 
10 mg/kg disulfiram).
The samples were injected into the tail vein of each 
mouse for 2 weeks (every 3 days). At various time inter-
vals tumor volume was measured by a vernier caliper and 
calculated using the following equation:
V = (L × W2) × 0.5 where L is the length and W is the 
width of the tumor [25, 26].
Animals were sacrificed 2  weeks after drug adminis-
tration using diethyl ether anesthesia and the size and 
weight of tumors were analyzed.
All the ethical and the humanity considerations were 
performed according to the Helsinki humanity research 
declaration during the experiments and the euthanasia of 
the animals. All the animals’ experiments were approved 
by the Ethics Committee of the Tehran University of 
Medical Sciences. All experiments were performed on 
BALB/c mice housed in cages in a temperature controlled 
room (23 ± 2 °C) with a light/dark cycle of 12/12 h.
H&E staining
For H&E staining, paraffin-embedded sample slides were 
deparaffinized, hydrated, and then stained with hematox-
ylin for 1 min. After rinsing, the slides were stained with 
eosin for 1  min, rinsed, and sealed with coverslips and 
analyzed using optical microscopy [25, 26].
Statistical analysis
All the results are the mean ± SD of three independent 
experiments. The significance of differences (p  <  0.05) 
between experimental variables was determined by the 
use of two-tailed Student’s test (SPSS.16). The statistical 
significance was indicated by p < 0.05.
Results
Characterization of PLGA‑PEG‑folate conjugate
1H NMR spectra of PLGA-PEG-folate was obtained using 
the Avence® (500 MHz; CDCl3) and is presented in Fig. 2. 
The folate group of polymer shows typical peaks of 6, 7, 8, 
9, 10 (2.34, 7.68, 6.60, 4.51 and 8.67 ppm) which represents 
the aromatic and pteridine protons of the folate. The typi-
cal peaks of PLGA at 5.20–5.40, 4.60–4.90 and 1.50 ppm as 
well as PEG at 3.33 and 3.50 ppm were also detected [18].
FTIR studies were carried out to confirm the presence 
of amide linkage in polymer. Characteristic FTIR absorp-
tion bands of folate in PLGA-PEG-folate were observed 
at 1606 (Aromatic C  =  C bending) and 3423 (Amine 
N–H stretch). The presence of amide bond C  =  O 
stretch) between PLGA-PEG and PEG-folate linkages 
were observed at 1630 cm−1. The presence of PEG can be 
seen in 1091 cm−1 (C–O–C) and 1630 cm−1 (C = O). The 
presence of PLGA was confirmed by 2946 and 2992 cm−1 
peaks (Alkyl C-H stretch) (Fig. 3).
LC–MS analysis was carried out to compare the length 
of PLGA and synthetic polymer (PLGA-PEG-folate). The 
LC–MS spectrum of PLGA and PLGA-PEG-folate is pre-
sented in Figs. 4 and 5, respectively.
Two adjacent peaks are chosen and the number of pol-
ymer cleavage is calculated as follow:
where (n) indicates the number of polymer cleavages, (a) 
indicates the peak with greater scale and (b) indicates the 
peak with lower scale. The molecular weight of polymer 
is calculated as follow:
Where (M) indicates the molecular weight of polymer 
chain. The molecular weight of PLGA and PLGA-PEG-
folate were calculated 35.2 and 44.3  KDa, respectively. 
The molecular weight increase of PLGA-PEG-folate com-
pared to PLGA could be due to the addition of PEG chain 
and folate group. These information confirms that the 
synthesis of PLGA-PEG-folate was successfully accom-
plished. In order to purify the synthesized polymer and 
reduce the contaminants, several steps of washing and 
dialysis were performed. Finally, the absence of impuri-
ties such as solvents and byproducts was confirmed by 
spectrophotometry.
Characterization of nanoparticles
Two types of NPs were synthesized; disulfiram encapsu-
lated PLGA NPs (DS-P-NPs) and disulfiram encapsulated 
PLGA-PEG-folate NPs (DS-PPF-NPs). A combination of 
PLGA-PEG-folate and PLGA ranging from (1:1) to (1:10) 
was chosen for synthesis of DS-PPF-NPs. The size of NPs 
was subsequently analyzed to have a final diameter size 
of  ~200  nm. The results show that with a ratio of (1:5) 
the size of NPs was 204 nm so this ratio was chosen for 
synthesis of DS-PPF-NPs.The physicochemical charac-
teristics of NPs are represented in Table  1. The carbox-
ylic groups of PLGA create negative surface charge on 
the surface of NPs as detected with the zeta potential 
that showed a more negative value for DS-P-NPs rather 
than DS-PPF-NPs. This is logical since a ratio of (1:5) of 
PLGA-PEG-folate was used for preparation of DS-PPF-
NPs. The addition of folate on the surface of NPs would 
reduce the overall negative charge of NPs as the carbox-
ylic end of PLGA is partly covered with the addition of 
PEG-folate.
To determine the size range of NPs, SEM (Fig.  6a, b) 
and zeta sizer (Fig. 6c, d) were used. The results showed 
an average size of 165  nm (PDI: 0.32) for DS-P-NPs 
whereas the average particle size of DS-PPF-NPs was 




M = an − n
Page 7 of 18Fasehee et al. J Nanobiotechnol  (2016) 14:32 
Drug loading, encapsulation efficiency and release profile
The results of drug loading and encapsulation efficiency 
of NPs are presented in Table 1. The drug loading into the 
NPs was 5.35 ± 0.03 and 5.42 ± 0.06 % for DS-P-NPs and 
DS-PPF-NPs, respectively. Encapsulation efficiency of 
NPs was 58.85 ± 1.01 and 59.62 ± 0.66 % for DS-P-NPs 
and DS-PPF-NPs, respectively. The dialysis against water 
was used as the final step in preparation of PLGA NPs. 
The dialysis was carried out for 24 h to ensure no trace of 
DMSO in NPs. It is assumed that the low encapsulation 
efficiency of disulfiram into the PLGA NPs is the result of 
disulfiram release from NPs in the dialysis period.
Considering that the controlled and continuous drug 
release is essential for the success of pharmaceuticals; 
we further examined the drug release profile of the NPs. 
Both DS-P-NPs and DS-PPF-NPs showed an initial burst 
release effect. During the first sampling time (24 h), disul-
firam release was 26.33 and 28.33  % for DS-P-NPs and 
DS-PPF-NPs, respectively. After 120  h, 39.3 and 43.3  % 
of encapsulated disulfiram released from DS-PPF-NPs, 
respectively (Fig. 7a, b).
Uptake of DS‑PPF‑NPs by cells (MCF7)
To investigate whether disulfiram-encapsulated NPs were 
internalized into the breast cancer cell line MCF7, cellular 
uptake of FITC labeled DS-P-NPs and FITC labeled DS-
PPF-NPs were analyzed by flowcytometry and fluorescent 
imaging microscopy. As shown in Fig. 8a, the cells incu-
bated with FITC labeled DS-P-NPs and FITC labeled DS-
PPF-NPs exhibited 11.2 and 21.02 % fluorescent intensity, 
respectively while untreated control cells didn’t show any 
FITC-fluorescent signal (RN1 = 1.38 %). The uptake rate 
of FITC labeled DS-PPF-NPs was significantly (p < 0.05) 
higher than FITC labeled DS-P-NPs (Fig. 8b).
Figure  8c shows that in the presence of folate, there 
is no difference between uptake of DS-P-NPs and 
Fig. 2 The structure of PLGA‑PEG‑folate and its proton’s position (a), the 1H NMR spectra of PLGA‑PEG‑folate (b). The peak positions in spectra cor‑
respond to the proton positions in PLGA‑PEG‑folate structure
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DS-PPF-NPs by MCF-7 cells. However when folate elimi-
nated from the medium, the uptake of DS-PPF-NPs was 
increased compared to DS-P-NPs. It is documented that 
PLGA NPs could cross the cell membrane even with-
out targeting agents [27]. However, it is assumed that 
the addition of folate agent on the surface of NPs would 
increase the uptake of NPs by FR positive cells.
The Uptake of FITC labeled DS-P-NPs and FITC 
labeled DS-PPF-NPs were also evaluated by fluorescent 
imaging microscopy (Fig.  9). The results showed that 
both FITC labeled DS-P-NPs and FITC labeled DS-PPF-
NPs were internalized into the MCF7 cells effectively.
Apoptosis induction by NPs
Apoptosis assay was performed by Chromatin Condensa-
tion/Dead Cell Apoptosis Kit. The double stain Hoechst 
33342 and PI render is a rapid and convenient assay for 
apoptosis and it is based on the fluorescent detection of 
the compacted state of chromatin in apoptotic cells [32]. 
Hoechst 33342 stains the condensed chromatin in apop-
totic cells (Q4) more radiantly than the chromatin in nor-
mal cells (Q3) while PI is only permeable to dead cells 
(Q1 and Q2). The result showed that total early and late 
apoptosis were 33.2 % and 45.8 % for DS-P-NPs and DS-
PPF-NPs, respectively (Fig. 10a). Neither PLGA NPs nor 
PPF-NPs cause apoptosis in MCF7 cells. The difference 
between DS-P-NPs and DS-PPF-NPs in apoptosis index 
was significant at p < 0.05 (Fig. 10b).
ROS activity and colony formation
Induction of ROS generation has been postulated to be 
an essential mechanism by which disulfiram initiate the 
apoptotic process. The ROS activity of MCF7 cells incu-
bated with free disulfiram, DS-P-NPs and DS-PPF-NPs 
were investigated. The result showed that with disul-
firam concentration of 250  nM, the intracellular ROS 
level was increased to 156, 184 and 196  % when MCF7 
cells were treated with free disulfiram, DS-P-NPs and 
DS-PPF-NPs, respectively (Fig.  11a). At the concentra-
tion of 500 nM, the intracellular ROS level of MCF7 cells 
treated with free disulfiram, DS-P-NPs and DS-PPF-NPs 
was increased to 510, 530 and 586  %, respectively. The 
results showed significant increase in ROS activity in DS-
P-NPs and DS-PPF-NPs groups compare to free disulfi-
ram at 250  nM (p  <  0.05). At 500  nM concentration of 
disulfiram, the ROS activity in DS-PPF-NPs was signifi-
cantly higher compare to DS-P-NPs and free disulfiram 
(p < 0.05).
To examine the ability of DS-P-NPs and DS-PPF-
NPs to induce reproductive death in breast cancer cells, 
MCF7 cells were exposed to the free disulfiram, DS-P-
NPs and DS-PPF-NPs at 250 nM concentration of disul-
firam equivalent for 12 h; the treated cells were collected 
and cultured in drug-free medium for 14 days. The MCF7 
colony number for free disulfiram and both disulfiram 
encapsulated NPs (DS-P-NPs and DS-PPF-NPs) was 
totally eradicated (Fig. 11b).
Fig. 3 The FTIR spectra of PLGA‑PEG‑folate
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MTT assay
For analyzing the in  vitro cytotoxic effect of DS-P-NPs 
and DS-PPF-NPs, MTT cell proliferation assay was 
performed using two breast cancer cell lines including 
MCF7 and 4T1. In order to analyze the potential cyto-
toxicity of NPs without drug, PPF-NPs (blank NPs) was 
synthesized and used as control sample. Figure 12 shows 
the in  vitro cytotoxic effect of DS-P-NPs, DS-PPF-NPs, 
PPF-NPs and free disulfiram on MCF7 and 4T1 cells. The 
results indicated that both DS-PPF-NPs and DS-P-NPs 
had higher cytotoxicity compared to free disulfiram. At 
500  nM concentration of disulfiram, the cell viability of 
MCF7 was 68.13 % for free disulfiram compared to 27.6 
and 35.6 % for DS-PPF-NPs and DS-P-NPs, respectively 
(Fig. 12a). For 4T1 cells, the cell viability at 500 nM con-
centration of disulfiram was 46.15  % for free disulfiram 
compared to 31.57 and 45.7 % for DS-PPF-NPs and DS-
P-NPs, respectively (Fig. 12b).
Also to determine if blank NPs have any cytotoxic 
effect, MCF7 and 4T1 cells were treated with different 
concentrations of PPF-NPs (0, 0.6, 1.2, 1.8, 2.4, 3, 4.5, 6, 
7.5, 9, 12 μg/ml). The results showed that PPF-NPs did 
not have any cytotoxic effects neither on MCF7 nor 4T1 
cells.
Acute and chronic toxicity
The in  vivo toxicity of DS-PPF-NPs was assessed follow-
ing of the injections of the drug into mice through acute 
and chronic toxicity evaluation. The initial given dose 
was 2000  mg/kg of DS-PPF-NPs which corresponded 
to 100  mg/kg equivalent of disulfiram. No death or loss 
of body weight was detected in this group of animals. 
To evaluate any possible abnormalities in hematologi-
cal markers of this group, complete blood analysis was 
performed. For 100  mg/kg group, reduction in SGOT, 
increase in SGPT, reduction in ALP and direct bilirubin, 
increase in albumin and total protein, decrease in total leu-
kocyte count and mean corpuscular hemoglobin concen-
tration were observed. Based on these results we decrease 
the dose of injection to 12.5, 6 and 3 mg/kg equivalent of 
disulfiram. For 12.5 mg/kg, increase in albumin and total 
protein and decrease in total leukocyte count and mean 
Fig. 4 The LC–MS spectrum of PLGA. The Counts vs. Mass‑to‑Charge (m/z) from 450 to 1450 (a) and 670 to 820 (b) is presented
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corpuscular hemoglobin concentration were detected. No 
sign of any abnormality in the other groups i.e. 6 and 3 mg/
kg equivalent of disulfiram were observed (Table 2). There-
fore, the initial dose for chronic toxicity test was chosen as 
6, 3, 1.5, and 0.75 mg/kg equivalent of disulfiram from DS-
PPF-NPs. To investigate the chronic toxicity of blank NPs 
(PPF-NPs), the same amount of PPF-NPs (6 mg/kg equiva-
lent of disulfiram) was injected to the control group. The 
results showed no significant hematological abnormality 
in any of the animal groups (Table 3).
Inhibition of tumor growth in mouse model
The inhibition of breast cancer tumor growth in BALB/c 
mice (using 4T1 cells) was performed with 10  mg/
kg disulfiram equivalent injection of DS-P-NPs and 
DS-PPF-NPs into tail vein of animals. The 10  mg/kg of 
disulfiram equivalent was chosen as the chronic toxic-
ity. The same amount of free disulfiram was dissolved 
in PBS and injected into tail vein of animals in order to 
compare the tumor inhibition efficacy of free disulfiram 
with the DS-P-NPs and DS-PPF-NPs. The results showed 
Fig. 5 The LC–MS spectrum of PLGA‑PEG‑folate. The Counts vs. Mass‑to‑Charge (m/z) from 400 to 1250 (a) and 770 to 915 (b) is presented
Table 1 Average particle size, drug loading, encapsulation efficiency and zeta potential of DS-P-NPs and DS-PPF-NPs
NPs Drug loading (%) Encapsulation efficiency (%) Average particle size (nm) Zeta potential
DS‑P‑NPs 5.35 ± 0.03 58.85 ± 1.01 165 −11.22 ± 0.84
DS‑PPF‑NPs 5.42 ± 0.06 59.62 ± 0.66 204 −5.24 ± 0.62
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that compare to free disulfiram, DS-P-NPs and DS-PPF-
NPs significantly inhibited the growth of tumor in mice 
(Fig. 13a). Compare to the control (blank NPs) and free 
disulfiram groups, the cancerous cells in IV injection of 
DS-P-NPs and DS-PPF-NPs show signs of necrotic cells 
(Fig. 13b).
Fig. 6 SEM image of DS‑P‑NPs (a), DS‑PPF‑NPs (b), average particle size of DS‑P‑NPs (c), average particle size of DS‑PPF‑NPs (d)
Fig. 7 In vitro disulfiram’s release curves from DS‑P‑NPs (a) and DS‑PPF‑NPs (b)
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After 2  weeks of injection, the volume of tumors was 
492  ±  23.09  mm3 for control group while the tumor 
size of 123 ± 5.16, 164 ± 24.5 and 408 ± 31.3 mm3 was 
measured for DS-PPF-NPs, DS-P-NPs and free disul-
firam injection groups, respectively (Fig.  13c). Besides, 
no sign of toxicity such as body weight loss was detected 
in the animals group with DS-P-NPs and DS-PPF-NPs 
injection.
The tumor weight at the final stage of experiment were 
measured and the results showed significant reduction in 
tumor weight in mice with free disulfiram and disulfiram 
encapsulated NPs injection groups. Compare to free disul-
firam, both DS-P-NPs and DS-PPF-NPs injection groups 
results more reduction in tumor weight (Fig. 13d). The sur-
vival rate of mice in disulfiram injection group was reduced 
compare to control, DS-P-NPs and DS-PPF-NPs (Fig. 14).
Fig. 8 The results of flowcytometery analysis indicating the uptake of FITC labeled DS‑P‑NPs and FITC labeled DS‑PPF‑NPs into MCF7 cells (a); the 
comparison between uptake rate of FITC labeled DS‑P‑NPs and FITC labeled DS‑PPF‑NPs. (b); the comparison between uptake of DS‑P‑NPs and DS‑
PPF‑NPs by MCF‑7 cells in the absence (−) and presence (+) of folate (c); The values are mean ± SD. *Indicates the significant difference between 
DS‑P‑NPs and DS‑PPF‑NPs
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Discussion
In its early discovery, disulfiram considered just as a drug 
for treatment of alcoholism. Recently with the evidence 
of its anticancer activity both in  vitro and in  vivo, this 
drug recognized as a “repurposing drug” for treatment 
of hematological malignancy and solid tumors. However, 
it’s instability in gastric environment and rapid degrada-
tion in blood stream hampered its clinical usage for can-
cer therapy. In this study, disulfiram was encapsulated 
into folate-receptor-targeted PLGA nanoparticles for its 
targeted delivery and controlled release into tumor and 
to inhibit its rapid degradation in blood stream.
Physiochemical properties of NPs such as their size 
and morphology have important role in their efficiency 
in drug delivery into tumor site. In solid tumors, several 
abnormalities could occur during blood vessel formation 
including deficiency in pericytes and aberrant basement 
membrane formation. These abnormalities result in leaky 
vessels with gap size of 220 nm to 1.2 μm between adja-
cent endothelial cells. The NPs with the size of 220 nm or 
smaller have access to the tumor that has a higher reten-
tion time than normal tissues (EPR effect) [4, 20]. The 
particle size of <10 nm can help for a faster renal clear-
ance of NPs [4, 20]. The particle size of >220 nm reduce 
the chance of the NPs to pass through the leaky vascula-
ture system of tumors [4, 20]. Moreover, the larger NPs 
may eliminate from blood by phagocytic uptake and 
reticuloendothelial system (RES) [28]. Therefore, the 
best particle size for delivery purposes into solid tumors 
should be in the range of 10–220 nm [17, 20]. The nano-
precipitation method for disulfiram encapsulated NPs 
synthesis resulted in uniform morphology and proper 
particle size which would facilitate their passage through 
leaky vessels in tumor tissue using EPR effect. The larger 
size of DS-PPF-NPs compared to DS-P-NPS might be 
because of the outside orientation of the PEG-folate moi-
eties on the surface of NPs. The higher drug content and 
encapsulation efficiency of DS-PPF-NPs could be due 
to its larger particle size. This is previously reported by 
other investigations that the PLGA-PEG-folate has larger 
Fig. 9 The fluorescent imaging of MCF7 cells containing FITC labeled DS‑P‑NPs and FITC labeled DS‑PPF‑NPs
Fig. 10 Apoptosis assay by Hoechst 33342 and PI using flowcytome‑
tery on MCF7 cells treated with PLGA NPs, PPF‑NPs, DS‑P‑NPs and DS‑
PPF‑NPs. FL2: PI, FL6: Hoechest 33342 (a); the comparison between 
apoptotic index of PLGA NPs, PPF‑NPs, DS‑P‑NPs and DS‑PPF‑NPs 
(b); the values are mean ± SD. *Indicates the significant difference 
between DS‑P‑NPs and DS‑PPF‑NPs
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particle size and higher loading efficiency compared to 
the PLGA NPs [18]. The rapid initial release of disulfi-
ram from NPs could be due to the adsorbed drug on the 
surface of NPs and the large surface to volume ratio of 
them [18]. After the burst release phase, a constant slow 
drug release profile was observed within the next 96 h of 
Fig. 11 The ROS activity in MCF7 cells treated with free disulfiram, DS‑P‑NPs and DS‑PPF‑NPs (a); the effect of free disulfiram, DS‑P‑NPs and DS‑PPF‑
NPs on the clonogenicity of MCF7 cells (b); the values are mean ± SD. *Indicates the significant difference between DS‑PPF‑NPs and free disulfiram
Fig. 12 Cytotoxicity of free disulfriam, DS‑P‑NPs and DS‑PPF‑NPs on MCF7 (a) and 4T1 cells (b); the values are mean ± SD. *p < 0.05 (for disulfiram); 
**p < 0.05 (for DS‑P‑NPs); ***p < 0.05 (for DS‑PPF‑NPs)
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Table 2 Acute toxicity of DS-PPF-NPs in different concentration (control, 3, 6, 12.5 and 100 mg/kg equivalent of disulfi-
ram) on hematological markers in mice
The values are mean ± SD
* p < 0.05 compared to control
Parameter Groups








Animal weight (g) 22.3 ± 1.9 22.7 ± 3.6 21.4 ± 2.2 22.9 ± 2.4 23.2 ± 1.8
Urea (mg/dL) 63.3 ± 7.6 75.0 ± 0.0 63.3 ± 10.4 65.0 ± 8.7 64.7 ± 6.5
Cr (mg/dL) 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.1 0.5 ± 0.1
ALP (U/L) 571.7 ± 92.9 478.3 ± 100.5 470.0 ± 111.7 583.0 ± 91.2 262.0 ± 39.3 *
SGOT (U/L) 396.7 ± 177.9 410.0 ± 91.7 293.3 ± 7.6 396.0 ± 152.7 * 75.0 ± 6.0 *
SGPT (U/L) 41.7 ± 18.9 63.3 ± 15.3 53.3 ± 10.4 65.0 ± 5.0 85.0 ± 6.2 *
D. BIL (mg/dL) 0.5 ± 0.1 0.4 ± 0.1 0.4 ± 0.0 0.4 ± 0.0 0.2 ± 0.0 *
ALB (mg/dL) 2.5 ± 0.0 3.3 ± 0.6 3.0 ± 0.5 5.0 ± 0.0 * 4.7 ± 0.6 *
Total protein (mg/dL) 4.8 ± 0.6 4.5 ± 0.0 4.2 ± 1.5 7.3 ± 0.2 * 6.6 ± 0.3 *
Glucose (mg/dL) 208.3 ± 70.8 271.7 ± 102.1 265.0 ± 98.4 243.0 ± 20.8 183.0 ± 35.1
WBC (1000/mm3) 12.8 ± 3.6 11.2 ± 0.8 12.3 ± 0.9 5.4 ± 0.7 * 3.6 ± 0.2 *
RBC (Millin/mm3) 9.5 ± 0.3 8.7 ± 0.5 8.3 ± 0.5 8.7 ± 0.2 9.5 ± 0.8
HGB (mg/dL) 15.2 ± 0.1 13.9 ± 0.7 13.0 ± 0.9 13.2 ± 0.8 14.4 ± 1.3
HCT (%) 42.5 ± 0.8 44.9 ± 2.3 44.1 ± 2.8 37.2 ± 2.4 39.7 ± 2.8
MCV (FL) 44.6 ± 0.5 52.0 ± 0.5 53.3 ± 0.3 42.8 ± 2.0 42.0 ± 1.6
MCHC (mol/L) 31.7 ± 0.3 30.9 ± 0.5 30.5 ± 0.2 15.2 ± 0.6* 15.2 ± 0.5*
Plt (1000/mm3) 1114.0 ± 77.8 744.0 ± 127.8 816.3 ± 71.6 1028.7 ± 124.4 * 880.7 ± 55.2 *
Table 3 Chronic toxicity of DS-PPF-NPs in different concentration (control, 0.75, 1.5, 3 and 6 mg/kg equivalent of disulfi-
ram) on hematological markers in mice
The values are mean ± SD
* p < 0.05 compared to control
Parameter Groups








Animal weight (g) 23.3 ± 2.1 24.3 ± 2.5 22.1 ± 1.8 23.4 ± 1.2 20.2 ± 2.4
Urea (mg/dL) 66.7 ± 2.6 73.3 ± 14.4 75.0 ± 13.5 76.3 ± 10.3 75.0 ± 0.0
Cr (mg/dL) 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.0 0.5 ± 0.0
ALP (U/L) 505.0 ± 142.0 468.3 ± 93.2 457.5 ± 47.9 452.5 ± 128.5 437.0 ± 70.8
SGOT (U/L) 497.5 ± 101.0 500.0 ± 161.7 490.0 ± 0.0 505.0 ± 86.6 418.3 ± 2.6
SGPT (U/L) 68.8 ± 23.4 70.0 ± 30.9 81.7 ± 11.3 76.7 ± 20.7 60.0 ± 11.5
D. BIL (mg/dL) 0.6 ± 0.1 0.5 ± 0.0 0.5 ± 0.0 0.4 ± 0.1 0.5 ± 0.2
ALB (mg/dL) 2.4 ± 0.2 2.4 ± 0.4 2.3 ± 0.3 2.3 ± 0.3 2.9 ± 0.6
Total protein (mg/dL) 6.3 ± 1.8 5.3 ± 0.3 5.9 ± 0.6 5.5 ± 0.7 6.0 ± 1.2
Glucose (mg/dL) 220.0 ± 57.7 215.0 ± 85.6 197.5 ± 31.8 233.3 ± 6.8 215.0 ± 66.4
WBC (1000/mm3) 6.3 ± 0.1 7.4 ± 1.3 7.2 ± 2.0 7.1 ± 0.8 2.3 ± 7.5
RBC (Millin/mm3) 7.7 ± 0.2 8.2 ± 0.4 8.3 ± 0.2 8.0 ± 0.1 7.6 ± 0.6
HGB (mg/dL) 12.2 ± 0.4 12.1 ± 0.6 12.5 ± 0.3 12.2 ± 0.5 12.4 ± 1.0
HCT (%) 38.2 ± 1.6 38.7 ± 2.2 39.8 ± 1.4 38.5 ± 1.3 40.6 ± 3.3
MCV (FL) 49.3 ± 1.2 47.5 ± 0.4 47.8 ± 0.7 48.1 ± 1.3 52.0 ± 0.0
MCHC (mol/L) 31.8 ± 0.2 31.3 ± 0.8 31.5 ± 0.3 31.6 ± 0.3 27.4 ± 6.0
Plt (1000/mm3) 1028 ± 334.9 943 ± 231 1013 ± 143 1081 ± 327 881 ± 59.3
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experiment indicating a typical sustained and prolonged 
drug release which can be correlated to the drug diffu-
sion and matrix erosion mechanisms [18].
The results show that DS-PPF-NPs may have advan-
tage over DS-P-NPs in regards with the uptakes by 
MCF7 cells. MCF7 is a folate receptor positive cell line 
which expresses the folate receptor on its surface at a 
significant level. It seems that folate receptor-mediated 
endocytosis mechanism may have a role in cellular 
uptake of DS-PPF-NPs. We used folate to cover the sur-
face of the NPs as the folic acid is small, stable, inexpen-
sive and non-immunogenic molecule. Also, the folate 
receptor is overexpressed on the vast majority of cancer 
tissues while its expression is limited in healthy tissues 
and organs [21]. Folate receptors are highly expressed 
in epithelial, ovarian, cervical, breast, lung, kidney, 
colorectal and brain tumors [21]. Approximately, 30  % 
of breast cancers and 80 % of stage IV metastatic triple 
negative breast cancer (TNBC) tumors express folate 
receptor [29].
Fig. 13 The inhibition of breast cancer tumor growth in BALB/c mice using i.v. injection of blank NPs as control, disulfiram, DS‑P‑NPs and DS‑PPF‑
NPs (a); The histo‑pathological image (H&E staining) of tumor from control, disulfiram, DS‑P‑NPs and DS‑PPF‑NPs injection groups with 400 times 
magnification (b); the comparison between tumor volume of control, disulfiram, DS‑P‑NPs and DS‑PPF‑NPs injection groups (c); the comparison 
between tumor weight of control, disulfiram, DS‑P‑NPs and DS‑PPF‑NPs injection groups (d); the values are mean ± SD. *Indicates the significant 
difference between control and NPs (p < 0.05); **indicates the significant difference between disulfiram and NPs (p < 0.05)
Fig. 14 Survival rates of tumor bearing mice treated with PBS (con‑
trol), disulfiram, DS‑P‑NPs and DS‑PPF‑NPs
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DS-PPF-NPs induced more apoptosis and therefore has 
higher cytotoxicity compared to DS-P-NPs. It should be 
noted that for a similar amount of disulfiram, less DS-PPF-
NPs is needed rather than DS-P-NPs for apoptosis induc-
tion. It is apparent that DS-PPF-NPs could effectively deliver 
disulfiram into breast cancer cells (MCF7) and induce apop-
tosis. Additionally, the higher cytotoxicity of DS-PPF-NPs 
could be corroborated to the higher affinity of folate conju-
gated NPs for MCF7 cells [18, 20].The increase of ROS level 
induced by DS-PPF-NPs in comparison with free disulfiram 
is an indication that more active disulfiram was transformed 
into the cells to prompt higher ROS production.
The results of MTT assay show that disulfiram loaded 
NPs have more cytotoxic effect on breast cancer cell lines 
(MCF7 and 4T1) compared to free disulfiram. The cyto-
toxic effect of disulfiram loaded NPs clearly could not 
be because of the PLGA or PEG as they are both FDA-
approved biocompatible polymers. The trace amount of 
PVA which was used as emulsifier in NPs preparation 
process and remained in the NPs is not cytotoxic [18]. 
The higher cytotoxicity effect of disulfiram encapsu-
lated PLGA-NPs could be the result of their internaliza-
tion into cell by folate receptor mediated endocytosis. 
It is known that PLGA-NPs could show a higher cel-
lular uptake compared with the free drug itself [18, 20]. 
The higher cellular internalization of DS-PPF-NPs leads 
to a higher cellular uptake of the entrapped therapeutic 
agent [30], enabling them to escape from the effect of 
P-glycoprotein (P-gp) pumps and thereby showing higher 
cytotoxic effect compared to free disulfiram as reported 
previously [30, 31]. Thus, NPs may act as intracellular 
drug depots that would slowly release the encapsulated 
therapeutic agent into cellular cytoplasm leading to 
enhanced therapeutic efficacy of the drug.
The significant decrease in tumor volume would be an 
indication for efficient tumor growth inhibition caused by 
drug encapsulated nanoparticles. The observed anti-tumor 
effect of disulfiram encapsulated PLGA NPs could be 
attributed to their accumulation into tumor and preven-
tion of the fast drug degradation from the blood stream.
Considering tremendous effects of disulfiram against 
cancer cells, its robust history of being well-tolerated within 
human body, and its low price and availability in the market 
compared to other chemotherapy agents, it is expected that 
encapsulation of disulfiram into folate-receptor-targeted 
PLGA-PEG NPs could provide a tool for translation of this 
drug into clinical cancer therapeutics.
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